CLEW Registered for CE Expanding its Commercial Reach in the European market

To improve the efficiency of the European healthcare system, the innovative CLEWICU solution identifies patients with an increased likelihood of being diagnosed with respiratory failure or hemodynamic instability, prioritizes workflow and treatment, and optimizes the allocation of critical care resources from CLEW Registered for CE Expanding its Commercial Reach in the European market

Healthcare IT Today FDA Approves Use of AI Tool Predicting Adverse Events In ICU

CLEW trained its AI using data on nearly 100,000 patients in ICUs. The AI-based algorithms are machine-learning models trained to predict such problems hours in advance. The product, CLEW-ICU, integrates care delivered by local and remote teams. According to the vendor, this clearance is the FDA’s first for technology in this category. from Healthcare IT Today FDA Approves Use of AI Tool Predicting Adverse Events In ICU

HHM Global: CLEW Medical receives FDA approval for AI-based tech to support adult ICU patient assessment

The healthcare technology revolution: AI-assisted doctors CLEWICU is the industry’s first-ever cleared device for predicting the likelihood of patient deterioration up to 8 hours in advance based on hemodynamic instability, enabling earlier evaluation and subsequent care plans. from HHM Global: CLEW Medical receives FDA approval for AI-based tech to support adult ICU patient assessment

Request a Demo

"*" indicates required fields

Name*